Anton Alexander Nolte Peterlin

Dr. Anton Alexander Nolte Peterlin

Department of Veterinary and Animal Sciences, Copenhagen University, Copenhagen, Hovedstaden, Denmark
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2025 in Injury
Verified
Journal Article
Closed access
Anton Alexander Nolte PeterlinAnton Alexander Nolte Peterlin
Anton Alexander Nolte Peterlin
MMMartin A McNally
Martin A McNally
JFJamie Ferguson
Jamie Ferguson
HGHans Gottlieb
Hans Gottlieb
LJLouise Kruse Jensen
Louise Kruse Jensen

16 December 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
Anton Alexander Nolte PeterlinAnton Alexander Nolte Peterlin
Anton Alexander Nolte Peterlin
MMMartin A McNally
Martin A McNally
NHNicole Lind Henriksen
Nicole Lind Henriksen
SBSophie A. Blirup-Plum
Sophie A. Blirup-Plum
AJAnn Jørgensen
Ann Jørgensen
LJLouise Kruse Jensen
Louise Kruse Jensen
Background: Microbiological culture and histology are gold standards for diagnosing chronic osteomyelitis (cOM) and fracture-related infection (FRI). This study investigated whether combining these modalities within a single tissue sample provides additional insight into disease severity. We hypothesized that high neutrophil and osteoclast numbers correlate with culture-positive microbiology and that double-positive samples may indicate more severe disease. Methods: In this prospective single-centre study, adults undergoing surgery for confirmed FRI or cOM were included. Clinical and disease classification data (FRI and BACH) were recorded. Five deep-tissue samples were collected intraoperatively and divided for paired microbiological culture and histological assessment of neutrophil infiltration, according to international diagnostic guidelines. Results: Forty-one patients were included (11 cOM, 30 FRI) of whom 68% received preoperative antibiotics. Nineteen patients (46%) were identified as culture-positive, while 32 patients (78%) were histologically positive according to international diagnostic guidelines, respectively. Among the 205 samples, 31% were culture-positive, 56% histology-positive, and 26% double-positive. Histological scores were significantly higher in culture-positive samples (p < 0.001). Treatment failure occurred in seven patients (18%), all with FRI. Paired positive samples were associated with increased odds of clinical failure and earlier revision, with odds increasing 1.68-fold for each additional paired positive sample (95% CI, 1.10–2.77). Conclusions: The paired analysis demonstrated a strong concordance between culture-positivity and suppurative inflammation within the same sample. Combining microbiology and histology may help identify patients at increased risk of revision and enhance diagnostic certainty, particularly in patients identified as culture-negative.

27 January 2026 in APMIS
Verified
Journal Article
Open access
Anton Alexander Nolte PeterlinAnton Alexander Nolte Peterlin
Anton Alexander Nolte Peterlin
NHNicole L. Henriksen
Nicole L. Henriksen
JBJulie M. Birch
Julie M. Birch
MHMarie H. Hansen
Marie H. Hansen
KHKatrine T. Hartmann
Katrine T. Hartmann
LJLouise K. Jensen
Louise K. Jensen
Bone and joint infections (BJIs) are debilitating conditions that reduce quality of life. Key features include interosseous bacteria, biofilm formation, suppurative inflammation, and osteolysis. Traditionally, bacteria‐associated osteolysis has been attributed to RANKL‐mediated osteoclast activation, based largely on in vitro and murine studies, but emerging evidence challenges this view. In this translational study, a porcine implant‐associated osteomyelitis (IAO) model was combined with clinical fracture‐related infection (FRI) data to investigate mechanisms of bone loss. In the IAO model, RANKL signaling was inhibited using Denosumab, yet pathological and radiographic osteolysis remained unchanged. Local RANKL mRNA expression and active osteoclast numbers also did not correlate with bone destruction. In FRI patients, mRNA in situ hybridization showed that MMP1 expression was higher in osteolytic cases compared to non‐osteolytic ones, whereas RANKL expression did not differ. The technique revealed heterogeneous expression of MMP1 and RANKL , in contrast to uniform C3 expression. The number of active osteoclasts likewise did not correlate with osteolysis severity, and a patient with chronic osteomyelitis receiving Denosumab for osteoporosis still experienced extensive bone loss. These findings do not refute the RANKL–osteoclast pathway but indicate that bacteria‐associated osteolysis is multifactorial, shaped by inflammatory and osteoimmunological interactions, proteolysis, neutrophil activity, and impaired osteogenesis.

16 June 2025 in Journal of Bone and Joint Infection
Verified
Journal Article
Open access
PDF file
Anton Alexander Nolte PeterlinAnton Alexander Nolte Peterlin
Anton Alexander Nolte Peterlin
LJLouise Kruse Jensen
Louise Kruse Jensen
EGEmil Gleipner-Andersen
Emil Gleipner-Andersen
HGHans Gottlieb
Hans Gottlieb
Introduction: Diabetic foot osteomyelitis (DFO) is a severe complication of diabetic foot ulcers, leading to high morbidity, mortality, and major limb amputation risk. While limb-sparing surgery is well established, optimal wound closure and intraosseous antibiotic strategies remain under-explored and under-reported. This study evaluates a single-stage limb-sparing surgical approach incorporating primary closure and local intraosseous antibiotic therapy. Methods: This retrospective study included 97 DFO patients (2017–2024) treated using the CLOSE-UP (Conservative surgery, Local antibiotics, Oral versus intravenous antibiotics – OVIVA, Samples, Effective limb preservation, and closUre Primary) protocol, developed to standardize DFO surgery. The one-stage procedure involved bone sampling, local debridement or minor amputation (distal to the tarsometatarsal joint), antibiotic-loaded calcium sulfate–hydroxyapatite biocomposite application, and primary wound closure. Postoperatively, patients followed the OVIVA antimicrobial protocol: 1 week of intravenous (IV) therapy and 5 weeks of oral (empiric penicillin–cloxacillin) therapy. The primary outcome was treatment failure within 1 year, with a minimum follow-up of 12 months. Results: Clinical failure occurred in 13 patients (13.4 %), with only 4 patients (4.1 %) requiring major amputation. Peripheral arterial disease was present in 24 patients (24.7 %) and was the only variable significantly associated with clinical failure (odds ratios: 10.21; P<0.01). The 1-year and 3-year mortality rates were 14.4 % and 35.9 %, respectively. Conclusions: The CLOSE-UP protocol demonstrated favourable outcomes. Given the high risk of mortality and limb loss in DFO, this structured approach has the potential to improve mobility, shorten rehabilitation, lower costs, and enhance quality of life. Further research, particularly randomized controlled trials, should focus on optimizing wound closure to improve long-term limb preservation and survival.

20 November 2025 in Materialia
Verified
Journal Article
Open access
KHKatrine Top Hartmann
Katrine Top Hartmann
MHMarie Høy Hansen
Marie Høy Hansen
Anton Alexander Nolte PeterlinAnton Alexander Nolte Peterlin
Anton Alexander Nolte Peterlin
JBJulie Melsted Birch
Julie Melsted Birch
BABent Aalbæk
Bent Aalbæk
LJLouise Kruse Jensen
Louise Kruse Jensen

18 June 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
LKLasse Bæk Krag
Lasse Bæk Krag
Anton Alexander Nolte PeterlinAnton Alexander Nolte Peterlin
Anton Alexander Nolte Peterlin
EGEmil Gleipner-Andersen
Emil Gleipner-Andersen
HGHans Gottlieb
Hans Gottlieb
Background: Bone and joint infections (BJIs) are a significant clinical challenge due to their tendency to recur, increased healthcare expenses, reduced quality of life, and mortality. Patients with BJIs are a heterogeneous group due to their different clinical presentations as well as patient-related risk factors. Empiric antibiotic regimens are commonly based on deductions from in vitro microbiologic findings, despite the fact that their relative efficacy and optimal antibiotic choices are underexplored. Methods: This retrospective cohort study included 521 patients surgically treated for BJIs at a specialized orthopedic infection unit between 2016 and 2023. Treatment strategies were guided by the Oral Versus Intravenous Antibiotics for Bone and Joint Infection (OVIVA) trial. All patients received a narrow-spectrum Gram-positive–targeted empiric systemic antibiotic regimen determined according to regional recommendations in collaboration with infectious disease specialists. The primary outcome was clinical failure within one year, with a minimum follow-up of 12 months. For the analyses, the patients were divided into three groups based on microbiological susceptibility: susceptible (SusEmp), non-susceptible (NonSus) and culture-negative (CulNeg) patients. Results: The three groups were found to differ significantly in seven patient-related factors: sex, age at primary operation (OP age), BMI, ASA group, diabetes status, peripheral arterial disease status (PAD), and endocrinopathy status (other than diabetes). In performing multivariate analyses, OP age was found to be independently associated with the overall failure rate (p = 0.04) and ASA group (p = 0.047), and PAD (p = 0.043) was independently associated with the secondary outcome of proximal amputation. Patients with non-susceptible pathogens (NonSus) had more than twice the odds of clinical failure (OR: 2.10; 95% CI: 1.12–3.95) and nearly fivefold higher odds of secondary proximal amputation (OR: 4.95; 95% CI: 1.41–23.2) compared with patients with susceptible pathogens (SusEmp). Conclusions: The current study demonstrates that a large group of patients can presumably be treated safely with a more restrictive narrow approach. More studies are needed to identify subgroups suited for the safe use of a narrow-spectrum empiric regimen, hereby reserving the broad-spectrum antibiotics for patients with the right indications and for whom it would have a positive effect on the clinical outcome. Such an approach would justify a more restrictive stewardship of broad-spectrum antibiotic use without negatively impacting patient outcomes.